Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Xian-Ping Lu | Founder, Chairman, GM, CEO & President | -- | -- | 1964 |
| Mr. Jian-Xun Li BA.CFA | VP, Deputy GM, CFO & Director | -- | -- | 1971 |
| Dr. Desi Pan | VP, Deputy GM, Chief Scientific Officer and Head of the Early Research & Development Center | -- | -- | 1971 |
| Ms. Ou Hai | VP, Deputy GM, Secretary of the Board, Head of Legal & Intellectual Property Department and Director | -- | -- | 1979 |
| Dr. Zhi-Bin Li Ph.D. | VP, Deputy GM and Head of Product Development & Production | -- | -- | 1965 |
| Mr. Liangji She | VP, Deputy GM & Head of Oncology Division | -- | -- | 1966 |
| Mr. Libin Zhang | VP, Deputy GM & Head of Metabolic Diseases Division | -- | -- | 1973 |
| Dr. Leming Shi | Co-Founder | -- | -- | -- |
| Dr. Weiming Hu | Co-Founder | -- | -- | -- |
| Mr. Ji-Hui Yi MS | Vice President of Sales & Marketing | -- | -- | -- |
Shenzhen Chipscreen Biosciences Co., Ltd.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 1,057
Description
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; and chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor. The company also develops CS23546, a small molecule PD-L1 inhibitor for CS23546 is a small molecule PD-L1 inhibitor; CS32582, a highly selective small molecule allosteric inhibitor of tyrosine kinase 2; CS12192, a highly selective JAK3 kinase inhibitor; and other drugs, such as CS12088 and CS23074. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available